Brief: Supernus Announces Fourth Quarter And Full Year 2022 Financial Results
28/02/2023 21:53
Feb 28 (Reuters) - Supernus Pharmaceuticals Inc
SUPN.O :
* SUPERNUS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL
RESULTS
* SUPERNUS PHARMACEUTICALS INC - SEES ABOUT 30% GROWTH AT
MIDPOINT
OF FY 2023 TOTAL REVENUE GUIDANCE COMPARED TO FY 2022, EXCLUDING
REVENUES OF TROKENDI XR
* SUPERNUS PHARMACEUTICALS INC - QTRLY EARNINGS PER SHARE
$0.43
* SUPERNUS PHARMACEUTICALS INC - AT DECEMBER 31, 2022, CO'S
CASH,
CASH EQUIVALENTS, CURRENT AND LONG-TERM MARKETABLE SECURITIES
ARE ABOUT $555.2 MILLION
Source text for Eikon: ID:nGNX3S2BTM
Further company coverage: SUPN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing